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The author of the above-mentioned paper
would like to make the following adjustments
to their article.
In the Results section, under ‘Predefined
Laboratory Abnormality Criteria’ and the
subsection ‘Liver Enzymes’, the sentence in
the first paragraph ‘‘…the proportion of
patients whose last ALT measurement was C3
times the ULN were 0.8% and 0.6%, respectively
[between-group difference 0.0]….’’, should state
the ALT between-group difference as 0.2, rather
than 0.0.
In Table 3, the difference between Sitagliptin
and Non-exposed (95% CI) for Neoplasms
Benign, Malignant and Unspecified should
read 0.5 (0.0, 1.0), rather than 0.6 (-0.0, 1.2).
In Table 5, the lower bound for Dyspepsia
should read 0.1, rather than 0.0.
In Table 6 of the Appendix, the number of
patients (N) is stated incorrectly in the second
and third sections of the table. The N values in
all sections should read: Sitagliptin group
(N = 7,726) and Non-exposed group
(N = 6,885).
In Table 7 of the Appendix, the lower bound
for Dyspepsia should read 0.1, not 0.0. Also,
footnote ‘c’ should include ‘‘gastrointestinal
pain’’.
The authors thank Springer Healthcare for
publishing the corrections.
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